A Phase I Clinical Trial of AAV2‐BDNF Gene Therapy for Alzheimer's Disease: Findings
AAV2-BDNF gene therapy to the entorhinal cortex in mild AD has been safe to date and restores FDG-PET activity in the treated brain region. BDNF gene therapy offers the potential to prevent neuronal loss, activate neuronal function and restore synapses, representing a possible neuro-restorative treatment for AD and MCI.
Authors
- Russell R. Lonser (ORCID: https://orcid.org/0000-0002-8007-707X)
- M H Tuszynski
- Gabriel C. Léger (ORCID: https://orcid.org/0000-0001-7900-3957)
- Douglas W. Scharre
- Krystof S Bankiewicz
- J. Bradley Elder
Institutions
- United States Department of Veterans Affairs (US)
- The Ohio State University Wexner Medical Center (US)
- University of California San Diego (US)
- The Ohio State University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101305
- Primary Topic
- Nerve injury and regeneration
- Type
- article
- Field-Weighted Citation Impact
- 0.00